Prelude Therapeutics (PRLD) Current Deferred Revenue (2024 - 2026)

Prelude Therapeutics has disclosed Current Deferred Revenue across 3 years of filings, most recently posting $31.0 million for Q1 2026.

• Current Deferred Revenue for Q1 2026 came in at $31.0 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $31.0 million (changed N/A YoY), and the FY2025 annual result was $33.7 million, changed N/A from the prior year.
• Current Deferred Revenue came in at $31.0 million for Q1 2026 at Prelude Therapeutics, down from $33.7 million in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $33.7 million in Q4 2025 to a low of $3.0 million in Q2 2024.
• The 3-year median for Current Deferred Revenue is $31.0 million (2026), against an average of $22.6 million.